<DOC>
	<DOC>NCT02122146</DOC>
	<brief_summary>To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.</brief_summary>
	<brief_title>A Study Of PF-06664178 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available Performance Status of 0 or 1 Adequate bone marrow, kidney and liver function Part 2 includes target expressing NSCLC, ovarian or breast cancer patients Brain metastases requiring steroids Major surgery, radiation therapy, or systemic anticancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas) Active and clinically significant bacterial, fungal, or viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ADC</keyword>
	<keyword>PF-06664178</keyword>
	<keyword>solid tumors</keyword>
	<keyword>tumors</keyword>
	<keyword>neoplasm metastasis</keyword>
	<keyword>NSCLC</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>OVCA</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>breast cancer</keyword>
</DOC>